JunFuture closes Pre-A to scale medical fluorocarbon production
The Nanjing company will fund research, GMP capacity and registration work in Taizhou.
JunFuture has completed a Pre-A round involving Taizhou Huayin Jintou and the Taizhou Angel Investment Fund, VCBeat reported on 16 November. The company raised tens of millions of yuan; an exact amount was not disclosed.
The funding will support core pipeline research, manufacturing capacity and registration filings for its fluorocarbon active-ingredient and pharmaceutical-excipient project in Taizhou.
Founded in 2021, JunFuture develops medical fluorocarbon materials and related pharmaceutical and device products. It is headquartered in Nanjing, with research and production operations in Zibo and Taizhou.
Use of funds
Core pipeline research and development
GMP capacity and registration filings in Taizhou